Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELESTE: AAVB-039 in Stargardt Disease
NCT07161544Phase 2Recruiting
- Sponsor
- AAVantgarde Bio
- Start
- Sep 2025
- Primary completion
- Jul 2032
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 3
01
Overview
A Phase 2 trial of AAVB-039 in Stargardt disease (STGD), sponsored by AAVantgarde Bio. Started Sep 2025; status: recruiting.
02
Drugs
AAVB-039
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT07161544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161544.